Navigation Links
TGen licenses first drug for patient use in clinical care
Date:5/4/2011

PHOENIX, Ariz. May 4, 2011 The Translational Genomics Research Institute (TGen) has licensed its first drug, a unique compound that targets cancer tumors by modifying the actions of proteins.

Today's announcement is another key fulfillment of TGen's primary mission: To move laboratory discoveries more rapidly into therapeutics that can immediately help patients improve their quality of life.

The drug, ONCO-101, is being licensed to Syracuse, N.Y.-based Oncoholdings Inc., a pharmaceutical company focused on the acquisition and development of innovative anti-cancer compounds.

Oncoholdings, in turn, has contracted with a TGen subsidiary, Scottsdale-based TGen Drug Development (TD2), to help guide continued pre-clinical tests, and eventually move ONCO-101 into first-in-human clinical trials, where it could immediate help cancer patients.

"This milestone is a significant accomplishment that validates the clinical groundwork we established when forming TGen," said Dr. Jeffrey Trent, TGen President and Research Director. "Because ONCO-101 could potentially change the way patients with ovarian and endometrial cancer are treated, we hope this is but the first of many compounds that benefit patients battling life-threatening illnesses."

Licensing ONCO-101 comes nearly nine years after the establishment of TGen, an integral piece of Arizona's bioscience initiative. The goals of that initiative are to: enable scientific discoveries; improve the quality of health care, especially for Arizona residents; and diversifying the state's knowledge-based economy.

ONCO-101 was developed at TGen in the course of research into the design of drugs that selectively target key proteins involved in cancers.

TGen granted Oncoholdings the exclusive license to further develop ONCO-101, an epigenetic agent, or compound, that decides how active proteins become. Currently, there are only four epigenetic drugs on the market, and they are only approved to treat blood cancers. ONCO-101 would be the first epigenetic agent to attack solid tumors.

"This class of therapeutic agents has yet to find its place in the market for the treatment of solid tumors," according to Jeffrey Evans, Ph.D. and Chief Operating Officer of Oncoholdings. "ONCO-101 works by allowing the regular function of normal cells, while disrupting the ability of abnormal cells to reproduce, effectively stopping the cancer."

Oncoholdings expects to announce the acquisition of its second group of products in the second quarter of 2011.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. The Indiana Clinical and Translational Science Institute (CTSI) Licenses GeneGos Eureka and MetaCore Platforms
2. Cells talk more in areas Alzheimers hits first, boosting plaque component
3. Study is the first to link sleep duration to infant growth spurts
4. Cedars-Sinai to hold first annual conference on stem cell therapies for neurological disorders
5. Success of First World Congress of Pediatric Urology underscores increasing importance of specialty
6. Alzheimers diagnostic guidelines updated for first time in decades
7. University of Granada researchers make the first bioartificial organ in Spain
8. First clinical trial of gene therapy for pain reported by U-M neurologists
9. Simple chemical cocktail shows first promise for limb re-growth in mammals
10. John Theurer Cancer Center first in New Jersey to offer complete capabilities of Provenge
11. Study provides first link between 2 major Parkinsons genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
(Date:6/23/2016)... 2016  The National Pharmaceutical Council (NPC) today ... policy research organization as its newest member.  ... vice president and chief scientific officer, Mallinckrodt Pharmaceuticals, ... NPC Board of Directors. ... joined us in support of our efforts to ...
Breaking Medicine Technology: